Illumina, Inc. (ILMN) – Financial and Strategic SWOT Analysis Review

Illumina, Inc. (ILMN) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
60
Medical Devices
United States

Illumina, Inc. (ILMN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Illumina, Inc. (Illumina) is a molecular diagnostics company. It develops, manufactures and markets life science tools and integrated systems for genetic variation and function analysis. The company offers solutions for copy number variation, single nucleotide polymorphism genotyping, gene expression profiling of DNA and RNA, and deoxyribonucleic acid methylation studies. Illumina offers its services to pharmaceutical companies, genomic research centers, academic institutions, biotechnology companies and clinical research organizations. The products offered by Illumina for genomic analysis include HiSeq 2500, NextSeq 500, MiSeq, HiScanSQ systems. The core technologies of the company include Sequencing by Synthesis (SBS), BeadArray and Real-Time PCR technology. The company’s products are distributed to various countries through its distributors in Europe, India, Israel, Korea, Malaysia, Greece, Turkey, Taiwan, Thailand, Vietnam, South Africa, Saudi Arabia, Russia, Ukraine, Belarus and other countries. Illumina is headquartered in San Diego, California, the US.

The company focuses on discover new opportunities and applications fueled by its next-generation sequencing. The this end the company recently in January 2015, the company expanded its next generation sequencing portfolio with the launch of HiSeq X five system, and HiSeq 3000/4000 systems.

Illumina, Inc. Key Recent Developments

Jan 27, 2015: Illumina Reports Record Financial Results for Fourth Quarter and Fiscal Year 2014
Jan 12, 2015: £15m boost for Scotland’s gene research
Jan 12, 2015: Illumina Expands World’s Most Comprehensive Next-Generation Sequencing Portfolio
Jan 12, 2015: Lockheed Martin and Illumina to Collaborate on Developing Genomics Solutions to Improve Public Health and Wellness
Dec 23, 2013: Illumina to Webcast Live Presentations at Upcoming Events in January

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
Illumina, Inc. – Key Facts 6
Illumina, Inc. – Key Employees 7
Illumina, Inc. – Key Employee Biographies 8
Illumina, Inc. – Major Products and Services 10
Illumina, Inc. – Medical Equipment Pipeline Products Data 12
Illumina, Inc. Pipeline Products by Equipment Type 12
Illumina, Inc. Pipeline Products by Development Stage 13
Illumina, Inc. – History 14
Illumina, Inc. – Company Statement 22
Illumina, Inc. – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Illumina, Inc. – Key Manufacturing Facilities 26
Section 2 – Company Analysis 27
Illumina, Inc. – Business Description 27
Illumina, Inc. – Corporate Strategy 28
Illumina, Inc. – SWOT Analysis 29
SWOT Analysis – Overview 29
Illumina, Inc. – Strengths 29
Strength – Unique Technology Platforms 29
Strength – Increased Revenue from Sequencing Products 29
Strength – Intellectual Property Portfolio 29
Illumina, Inc. – Weaknesses 30
Weakness – Credit Risk Increase 30
Weakness – Patent Infringement 30
Illumina, Inc. – Opportunities 31
Opportunity – New Product Launches 31
Opportunity – Strategic Acquisitions 31
Opportunity – Agreements and Collaborations 31
Illumina, Inc. – Threats 33
Threat – Rapid Technological Advancements 33
Threat – Competitive Landscape 33
Threat – Government Regulations 33
Illumina, Inc. – Key Competitors 34
Section 3 – Company Financial Ratios 35
Financial Ratios – Capital Market Ratios 35
Financial Ratios – Annual Ratios 36
Performance Chart 38
Financial Performance 38
Financial Ratios – Interim Ratios 39
Financial Ratios – Ratio Charts 40
Section 4 – Company’s Lifesciences Financial Deals and Alliances 41
Illumina, Inc., Medical Equipment, Deals By Year, 2009 to YTD 2015 41
Illumina, Inc., Medical Equipment, Deals By Type, 2009 to YTD 2015 42
Illumina, Inc., Recent Deals Summary 43
Section 5 – Company’s Recent Developments 44
Mar 03, 2015: Genome Analysis of Cancer Cells: Germany’s Biggest Sequencing Unit Established in Heidelberg 44
Jan 27, 2015: Illumina Reports Record Financial Results for Fourth Quarter and Fiscal Year 2014 45
Jan 12, 2015: Illumina Expands World’s Most Comprehensive Next-Generation Sequencing Portfolio 47
Dec 12, 2014: HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 49
Dec 03, 2014: Illumina and Sequenom Pool Noninvasive Prenatal Testing Intellectual Property and End Outstanding Patent Disputes 50
Oct 20, 2014: Illumina Reports Record Financial Results for Third Quarter of Fiscal Year 2014 51
Oct 15, 2014: Illumina Accelerator Announces Investment in Inaugural Startup Class 52
Sep 08, 2014: Actionable Genome Consortium Forms with Cross Disciplinary Leaders from World-Renowned Cancer Institutions 53
Aug 21, 2014: AstraZeneca announces partnership with Illumina to develop next generation gene sequencing panel for companion diagnostic tests 54
Aug 07, 2014: Global Collaboration Creates First Publicly Available Illumina HiSeq X Ten DNA Sequence Dataset 55
Section 6 – Appendix 56
Methodology 56
Ratio Definitions 56
About GlobalData 60
Contact Us 60
Disclaimer 60



List of Tables
Illumina, Inc., Key Facts 6
Illumina, Inc., Key Employees 7
Illumina, Inc., Key Employee Biographies 8
Illumina, Inc., Major Products and Services 10
Illumina, Inc. Number of Pipeline Products by Equipment Type 12
Illumina, Inc. Pipeline Products by Equipment Type 12
Illumina, Inc. Number of Pipeline Products by Development Stage 13
Illumina, Inc. Pipeline Products by Development Stage 13
Illumina, Inc., History 14
Illumina, Inc., Other Locations 23
Illumina, Inc., Subsidiaries 23
Illumina, Inc., Key Manufacturing Facilities 26
Illumina, Inc., Key Competitors 34
Illumina, Inc., Ratios based on current share price 35
Illumina, Inc., Annual Ratios 36
Illumina, Inc., Interim Ratios 39
Illumina, Inc., Medical Equipment, Deals By Year, 2009 to YTD 2015 41
Illumina, Inc., Medical Equipment, Deals By Type, 2009 to YTD 2015 42
Illumina, Inc., Recent Deals Summary 43
Currency Codes 56
Capital Market Ratios 56
Equity Ratios 57
Profitability Ratios 57
Cost Ratios 58
Liquidity Ratios 58
Leverage Ratios 59
Efficiency Ratios 59



List of Figures
Illumina, Inc. Pipeline Products by Equipment Type 12
Illumina, Inc. Pipeline Products by Development Stage 13
Illumina, Inc., Performance Chart (2010 – 2014) 38
Illumina, Inc., Ratio Charts 40
Illumina, Inc., Medical Equipment, Deals By Year, 2009 to YTD 2015 41
Illumina, Inc., Medical Equipment, Deals by Type, 2009 to YTD 2015 42

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.